For the first time in history, chronic diseases are killing us more than infectious diseases.

One reason is that vaccines, the first biologic revolution, have been so successful and prolific. There are today 29 vaccine-preventable diseases and over 80% of the world is vaccinated. Unfortunately, they have been limited exclusively to infectious diseases.


The innovation of complex biologics, particularly monoclonal antibodies (mAbs), manufactured in bioreactors comprise the second revolution and have been highly effective against certain chronic diseases. Unfortunately, they pose manufacturing challenges, are burdensome to administer, and are extremely expensive, which is why less than 1% of the world currently has the privilege of the medical benefits of mAbs, a small fraction of the global population who actually could benefit.

This leads us to the third biologic revolution.

With AIMs (active immunotherapy medicines), we are bringing the efficiency of vaccines – which are cheaper, more convenient and accessible – to chronic diseases which leads to a dramatic increase to that 1%. In this way, we do not aim to steal market share from current mAbs, but rather to expand the overall addressable market.

We call this expansive disruption.